Tscan Therapeutics Inc (TCRX) — Titan Protect Analysis

TCRX

Tscan Therapeutics Inc

Healthcare · ·

$0.98

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$63M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-1.09

Based on estimated future earnings — lower means cheaper

Rev Growth

-54.8%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-81.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$6.00

+511% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 4 analysts covering this stock

About Tscan Therapeutics Inc

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates

https://www.tscan.com

Country: United States Employees: 138 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.902

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.1356

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.736

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-66.3%

Historical annualised return based on price data

Max Drawdown

-90.0%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.06

Moves slightly more than the broader market

52W High

$2.57

62% below the year high

52W Low

$0.88

11% above the year low

Avg Volume

865,263

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.96

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

95.48

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

-2,967.3%

Profit from core operations before interest and tax

Free Cash Flow

$-84,107,624

Negative — the business is spending more than it generates

Revenue (TTM)

$9M

Total revenue over the last 12 months

Net Income

$-124,305,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$7.00

Target Median

$6.00

Target Low

$5.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go